The rise in prevalence of cancer across the globe and growing awareness of immune checkpoint inhibitors propel the product demand. Also, technological developments in screening procedures for cancer, increase in government initiatives to cure cancer, growing healthcare expenditures, and rise in public awareness further boost the market growth. However, the high cost associated with research activities is likely to restrain the industry growth.